secwatch.observer — SEC 8-K summary
======================================

Issuer:     Braveheart Bio, Inc. (BRVE)
CIK:        0002131524
Form:       8-K
Filed at:   2026-08-07T20:14:14+00:00
Accession:  0001628280-26-054842
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Braveheart Bio files amended charter and bylaws post-IPO, authorizing 500M common shares
--------------------------------------------------------------------------------

- Second amended and restated certificate of incorporation filed with Delaware on Aug 7, 2026, effective immediately prior to IPO completion.
- Authorizes 500,000,000 shares of common stock and 10,000,000 shares of undesignated preferred stock.
- Eliminates prior preferred stock series and removes stockholder ability to act by written consent or call special meetings.
- Amended and restated bylaws establish advance notice procedures for stockholder proposals and board nominations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2131524/000162828026054842/0001628280-26-054842-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2131524/000162828026054842/braveheart-closing8xk.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-054842

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer